95 assets in Glioma

Therapeutic assets addressing Glioma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Olutasidenib Glioma	Rigel Pharmaceuticals	P4	BBB (72)
Irinotecan Glioma	Kailin Yang, MD, PhD	P3	B (63)
Cyclophosphamide Glioma	Essen Biotech	P2	B (60)
Nivolumab Glioma	Jason J. Luke, MD	P2	B (59)
Ivosidenib Glioma	Jason J. Luke, MD	P2	B (58)
Cis-Diamminedichloroplatinum Ii Glioma	Eli Lilly and Company	P1/2	B (57)
Olaparib Glioma	University Health Network, Toronto	P2	B (57)
Palbociclib Glioma	National Cancer Institute (NCI)	P2	B (57)
Pembrolizumab Glioma	Essen Biotech	P2	B (57)
PI3K/MTOR INHIBITOR LY3023414 Glioma	National Cancer Institute (NCI)	P2	B (57)
Tazemetostat Glioma	National Cancer Institute (NCI)	P2	B (57)
Trametinib Glioma	Cancer Research UK	P2/3	B (57)
Cetuximab Glioma	Pfizer	P2	CCC (55)
Durvalumab Glioma	Eli Lilly and Company	P2	CCC (55)
Niraparib Glioma	University of Oklahoma	P2	CCC (55)
Binimetinib Glioma	Pfizer	P2	CCC (54)
Dabrafenib Glioma	Cancer Research UK	P2/3	CCC (54)
Microbubble Glioma	NaviFUS Corporation	P3	CCC (54)
Rvp-001 Glioma	Reveal Pharmaceuticals Inc.	P2	CCC (54)
Safusidenib Glioma	Nuvation Bio Inc.	P3	CCC (54)
Vemurafenib Glioma	Cancer Research UK	P2/3	CCC (54)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- Glioma	National Cancer Institute (NCI)	P2	CCC (53)
Chlorophyllin Copper Complex Sodium Glioma	Tata Memorial Centre	P2	CCC (53)
Ensartinib Glioma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Glioma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Glioma	National Cancer Institute (NCI)	P2	CCC (53)
Selpercatinib Glioma	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Glioma	National Cancer Institute (NCI)	P2	CCC (53)
Ulixertinib Glioma	National Cancer Institute (NCI)	P2	CCC (53)
Cobimetinib Glioma	Cancer Research UK	P2/3	CCC (52)
Entrectinib Glioma	Cancer Research UK	P2/3	CCC (52)
Capivasertib Glioma	National Cancer Institute (NCI)	P2	CCC (51)
Crizotinib Glioma	National Cancer Institute (NCI)	P2	CCC (51)
Dasatinib Glioma	National Cancer Institute (NCI)	P2	CCC (51)
Defactinib Glioma	National Cancer Institute (NCI)	P2	CCC (51)
Fexagratinib Glioma	National Cancer Institute (NCI)	P2	CCC (51)
Glucose, Anhydrous Glioma	Stanford University	P2	CCC (51)
Gsk-2636771 Glioma	National Cancer Institute (NCI)	P2	CCC (51)
Ipatasertib Glioma	National Cancer Institute (NCI)	P2	CCC (51)
Mannitol Glioma	Northwell Health	P2	CCC (51)
Osimertinib Glioma	National Cancer Institute (NCI)	P2	CCC (51)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Glioma	National Cancer Institute (NCI)	P2	CCC (51)
Pertuzumab Glioma	National Cancer Institute (NCI)	P2	CCC (51)
Relatlimab Glioma	National Cancer Institute (NCI)	P2	CCC (51)
Sapanisertib Glioma	National Cancer Institute (NCI)	P2	CCC (51)
Silevertinib Glioma	Black Diamond Therapeutics, Inc.	P2	CCC (51)
Trastuzumab Glioma	National Cancer Institute (NCI)	P2	CCC (51)
Trastuzumab Emtansine Glioma	National Cancer Institute (NCI)	P2	CCC (51)
Vismodegib Glioma	National Cancer Institute (NCI)	P2	CCC (51)
Adavosertib Glioma	National Cancer Institute (NCI)	P2	CCC (50)

Showing 1 to 50 of 95 assets

PreviousPage 1 of 2Next